Cargando…
Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report
INTRODUCTION: Gefitinib is a new molecular-targeted agent for the treatment of patients with advanced non-small cell lung cancer that fail to respond to conventional chemotherapy. Gefitinib is considered to be well tolerated and less toxic compared with conventional cytotoxic drugs. However, interst...
Autores principales: | Takamochi, Kazuya, Suzuki, Kazuya, Bashar, Abul Hasan Muhammad, Yajima, Kiyoshige, Mochizuki, Takahiro, Itaya, Toru, Funai, Kazuhito |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194710/ https://www.ncbi.nlm.nih.gov/pubmed/18021415 http://dx.doi.org/10.1186/1752-1947-1-138 |
Ejemplares similares
-
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007) -
Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma
por: Fujii, Yosuke, et al.
Publicado: (2017) -
Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
por: Kawagoe, Tetsuro, et al.
Publicado: (2020) -
Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020) -
Outcome and prognosis of secondary lung cancer surgery with interstitial lung disease
por: Ichinokawa, Hideomi, et al.
Publicado: (2022)